COLUMVI Patent Protection Prolonged: FDA's Usual Suspects
Published Date: 6/20/2025
Notice
Summary
The FDA has officially set the review period for COLUMVI, a human biological product, so its patent can be extended. This helps the company behind COLUMVI get extra time to protect their invention before generic versions can appear. If you’re involved in drug patents or healthcare, this timing update matters for future market competition and innovation.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Patent-Extension Step Opened for COLUMVI
The FDA has determined the regulatory review period for COLUMVI, a human biological product, so the company can submit applications to the U.S. Patent and Trademark Office to seek a patent extension that claims that product. This notice documents that formal step in the patent-extension process.
Timing Update Relevant to Market Competition
The FDA's determination affects timing for COLUMVI's patent-extension process, which the notice says gives the company extra time to protect the invention before generic versions can appear. If you work in drug patents, pharmaceuticals, or healthcare, this timing update is relevant to future market competition and innovation related to that product.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Previous / Next Documents
Previous: 2025-11320, Determination of Regulatory Review Period for Purposes of Patent Extension; TRUQAP
The FDA has officially set the review period for TRUQAP, a human drug product, so its patent can be extended. This helps the drug maker get extra time to protect their invention after the long approval process. If you’re involved in drug patents or development, this means important deadlines and opportunities to keep an invention exclusive and profitable.
Next: 2025-11322, Determination of Regulatory Review Period for Purposes of Patent Extension; BREYANZI
The FDA has officially set the review period for BREYANZI, a special medicine made from human cells. This means the company can ask for extra time on their patent to protect their invention. If approved, this could give them more exclusive rights before others can copy it, affecting when generic versions might appear and potentially impacting market competition and profits.